Association between transforming growth factor‐β1 polymorphisms and hepatocellular cancer risk: A meta‐analysis

• DOI: 10.1111/j.1872-034x.2011.00958.x
• Publication Date: 2012-01-18T13:04:12Z
• Authors: Tian‐Xin Xiang; Na Cheng; Xi‐Nv Li; Xiao‐Ping Wu
• Keywords: Hepatocellular cancer; Subgroup analysis; genetic model; Liver Cancer

Aim: The association between transforming growth factor‐β1 ( TGF‐β1 ) gene polymorphisms and hepatocellular cancer (HCC) risk has been widely reported, but results were somewhat controversial. To derive a more precise estimation of the relationship HCC risk, we conducted meta‐analysis all available studies relating C‐509T and/or T869C to developing HCC. Methods: Two investigators independently searched MEDLINE, PubMed, Web Science, Embase, CNKI (China National Knowledge Infrastructure) CBM (Chinese Biomedical Literature database) for period up August 2011. Result: A total nine case‐control articles identified. Five with 1825 cases 2869 controls polymorphism, six 536 1496 polymorphism included. In overall analysis, no significant was observed. Stratified analysis showed that present only in liver disease (T vs. C: odds ratio [OR] = 0.769, 95% confidence interval [CI] 0.661–0.895; TT CC: OR 0.570, CI 0.412–0.788; TT/TC 0.668, 0.523–0.854; TC/CC: 0.717, 0.550–0.934), not healthy controls. With respect decreased found recessive models disease. Conclusions: This supports may act protecting role susceptibility populations related